Pharmacological actions of cannabinoids.

By R. Pertwee. Handbook of Experimental Pharmacology, 2005

625 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology, Toxicology

View Paper: https://www.semanticscholar.org/paper/0b2c708a20ad63f1a2033437da12b8b70500a111

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Pertwee
2. K. Mackie
3. V. Di Marzo
4. R. Ross
5. George Kunos
6. Tamás F. Freund
7. I. Katona
8. R. Mechoulam

In Pharmacology

1. R. Pertwee
2. V. Di Marzo
3. K. Mackie
4. George Kunos
5. Tamás F. Freund
6. R. Ross
7. P. Pacher
8. S. Batkai

In Toxicology

1. George Kunos
2. Tamás F. Freund
3. I. Katona
4. V. Di Marzo

Citations in the corpus

• Immune System Dysregulation During Spaceflight: Potential Countermeasures for Deep Space Exploration Missions (2018, background): “They modulate cell function through a set of cannabinoid (CB) receptors, which are primarily expressed in tissue of the central and peripheral nervous system (CB1) and on immune cells (CB2) (136).”
• International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010, methodology): “Rimon-abant, which is a low-affinity antagonist of the vascular putative abn-CBD receptor (for review, see Pertwee 2005a; Ross, 2009), had no effect on GPR18-mediated microglial migration at concentrations up to 1 (cid:4) M (McHugh et al., 2010).”
• Neurobiological Interactions Between Stress and the Endocannabinoid System (2016, background): “CB2 receptors are mostly located in immune cells and, when activated, can modulate immune cell migration and cytokine release both outside and within the brain (Pertwee, 2005).”
• Endocannabinoid signaling as a synaptic circuit breaker in neurological disease (2008, background): “In addition, anandamide may also influence physiological and pathophysiological processes via activation of several other molecular target”
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin (2008, background): “…release of chemical messengers, in this case the release of cytokines from immune cells and may, in addition, affect immune function by modulating immune cell migration both within and outside the central nervous system (reviewed in Walter and Stella, 2004; Cabral and Staab, 2005; Pertwee, 2005a).”
• Cannabinoid pharmacology: the first 66 years (2006, background): “Since the discovery of CB1 and CB2 receptors, a great deal has become known about how these receptors signal and about their roles (reviewed in Howlett et al., 2002; Howlett, 2005; Pertwee, 2005b).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “Surprisingly, SR141716 and the CB2 antagonist SR144528 were also reported to have antiinflammatory effects (Smith et al., 2000, 2001), which may be attributed to their inverse agonist properties or to CB1/2 receptor-independent mechanisms (reviewed in Begg et al., 2005; Pertwee, 2005b,c).”